vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and LINKBANCORP, Inc. (LNKB). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $46.0M, roughly 1.9× LINKBANCORP, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 7.3%). LINKBANCORP, Inc. produced more free cash flow last quarter ($23.8M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.6%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
LINKBANCORP, Inc. is a US-based bank holding company that offers comprehensive retail and commercial banking services to individual consumers, small businesses, and mid-sized enterprises. Its core offerings include deposit accounts, lending products, wealth management solutions, and digital banking services, primarily serving customers across regional markets in Pennsylvania.
IOVA vs LNKB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $46.0M |
| Net Profit | — | $2.9M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 8.5% |
| Net Margin | — | 6.4% |
| Revenue YoY | 17.7% | 7.3% |
| Net Profit YoY | — | -61.2% |
| EPS (diluted) | — | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $46.0M | ||
| Q3 25 | $67.5M | $44.8M | ||
| Q2 25 | $60.0M | $42.3M | ||
| Q1 25 | $49.3M | $53.4M | ||
| Q4 24 | $73.7M | $42.9M | ||
| Q3 24 | $58.6M | $42.9M | ||
| Q2 24 | $31.1M | $41.3M | ||
| Q1 24 | $715.0K | $40.5M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | $-91.3M | $7.8M | ||
| Q2 25 | $-111.7M | $7.4M | ||
| Q1 25 | $-116.2M | $15.3M | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $-83.5M | $7.1M | ||
| Q2 24 | $-97.1M | $5.8M | ||
| Q1 24 | $-113.0M | $5.7M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 8.5% | ||
| Q3 25 | -140.7% | 22.3% | ||
| Q2 25 | -189.8% | 22.4% | ||
| Q1 25 | -245.8% | 36.0% | ||
| Q4 24 | -117.5% | 22.6% | ||
| Q3 24 | -152.1% | 21.3% | ||
| Q2 24 | -327.6% | 18.0% | ||
| Q1 24 | -16464.6% | 18.1% |
| Q4 25 | — | 6.4% | ||
| Q3 25 | -135.3% | 17.5% | ||
| Q2 25 | -186.2% | 17.5% | ||
| Q1 25 | -235.5% | 28.7% | ||
| Q4 24 | — | 17.7% | ||
| Q3 24 | -142.7% | 16.5% | ||
| Q2 24 | -312.2% | 14.1% | ||
| Q1 24 | -15800.8% | 14.1% |
| Q4 25 | — | $0.08 | ||
| Q3 25 | — | $0.21 | ||
| Q2 25 | $-0.33 | $0.20 | ||
| Q1 25 | $-0.36 | $0.41 | ||
| Q4 24 | $-0.24 | $0.21 | ||
| Q3 24 | $-0.28 | $0.19 | ||
| Q2 24 | $-0.34 | $0.16 | ||
| Q1 24 | $-0.42 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $52.3M |
| Total DebtLower is stronger | — | $177.3M |
| Stockholders' EquityBook value | $698.6M | $306.4M |
| Total Assets | $913.2M | $3.1B |
| Debt / EquityLower = less leverage | — | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $52.3M | ||
| Q3 25 | $300.8M | $194.2M | ||
| Q2 25 | $301.2M | $155.1M | ||
| Q1 25 | $359.7M | $220.2M | ||
| Q4 24 | $323.8M | $166.1M | ||
| Q3 24 | $397.5M | $191.2M | ||
| Q2 24 | $412.5M | $181.7M | ||
| Q1 24 | $356.2M | $172.3M |
| Q4 25 | — | $177.3M | ||
| Q3 25 | — | $102.3M | ||
| Q2 25 | — | $102.3M | ||
| Q1 25 | — | $102.7M | ||
| Q4 24 | — | $112.5M | ||
| Q3 24 | — | $102.4M | ||
| Q2 24 | — | $102.3M | ||
| Q1 24 | — | $102.2M |
| Q4 25 | $698.6M | $306.4M | ||
| Q3 25 | $702.3M | $305.5M | ||
| Q2 25 | $698.5M | $298.0M | ||
| Q1 25 | $767.9M | $294.1M | ||
| Q4 24 | $710.4M | $280.2M | ||
| Q3 24 | $773.5M | $277.4M | ||
| Q2 24 | $768.5M | $271.4M | ||
| Q1 24 | $680.0M | $268.2M |
| Q4 25 | $913.2M | $3.1B | ||
| Q3 25 | $904.9M | $3.1B | ||
| Q2 25 | $907.4M | $2.9B | ||
| Q1 25 | $966.7M | $2.9B | ||
| Q4 24 | $910.4M | $2.9B | ||
| Q3 24 | $991.1M | $2.9B | ||
| Q2 24 | $964.3M | $2.9B | ||
| Q1 24 | $869.8M | $2.8B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.33× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.38× | ||
| Q1 24 | — | 0.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $25.3M |
| Free Cash FlowOCF − Capex | $-61.9M | $23.8M |
| FCF MarginFCF / Revenue | -71.3% | 51.7% |
| Capex IntensityCapex / Revenue | 10.7% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 8.59× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $55.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $25.3M | ||
| Q3 25 | $-78.7M | $23.6M | ||
| Q2 25 | $-67.4M | $6.3M | ||
| Q1 25 | $-103.7M | $2.6M | ||
| Q4 24 | $-73.3M | $25.4M | ||
| Q3 24 | $-59.0M | $14.0M | ||
| Q2 24 | $-98.4M | $6.4M | ||
| Q1 24 | $-122.3M | $-771.0K |
| Q4 25 | $-61.9M | $23.8M | ||
| Q3 25 | $-89.5M | $23.2M | ||
| Q2 25 | $-74.9M | $6.1M | ||
| Q1 25 | $-109.9M | $2.2M | ||
| Q4 24 | $-77.5M | $22.6M | ||
| Q3 24 | $-61.3M | $13.1M | ||
| Q2 24 | $-98.9M | $6.3M | ||
| Q1 24 | $-126.5M | $-1.2M |
| Q4 25 | -71.3% | 51.7% | ||
| Q3 25 | -132.7% | 51.8% | ||
| Q2 25 | -124.9% | 14.5% | ||
| Q1 25 | -222.8% | 4.2% | ||
| Q4 24 | -105.1% | 52.6% | ||
| Q3 24 | -104.6% | 30.5% | ||
| Q2 24 | -317.9% | 15.3% | ||
| Q1 24 | -17685.3% | -3.0% |
| Q4 25 | 10.7% | 3.2% | ||
| Q3 25 | 16.1% | 0.8% | ||
| Q2 25 | 12.4% | 0.4% | ||
| Q1 25 | 12.6% | 0.7% | ||
| Q4 24 | 5.7% | 6.7% | ||
| Q3 24 | 3.9% | 2.1% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 583.4% | 1.1% |
| Q4 25 | — | 8.59× | ||
| Q3 25 | — | 3.01× | ||
| Q2 25 | — | 0.85× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 3.35× | ||
| Q3 24 | — | 1.97× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
LNKB
Segment breakdown not available.
